0001553350-22-000571.txt : 20220621 0001553350-22-000571.hdr.sgml : 20220621 20220621103017 ACCESSION NUMBER: 0001553350-22-000571 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220621 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220621 DATE AS OF CHANGE: 20220621 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MediXall Group, Inc. CENTRAL INDEX KEY: 0001601280 STANDARD INDUSTRIAL CLASSIFICATION: RAILROADS, LINE-HAUL OPERATING [4011] IRS NUMBER: 330864127 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-194337 FILM NUMBER: 221026483 BUSINESS ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 BUSINESS PHONE: 954-440-4678 MAIL ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 FORMER COMPANY: FORMER CONFORMED NAME: CONTINENTAL RAIL CORP DATE OF NAME CHANGE: 20140227 8-K 1 mdxl_8k.htm FORM 8-K
0001601280 false 0001601280 2022-06-21 2022-06-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

———————

FORM 8-K

———————

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2022

———————

MediXall Group, Inc.

(Exact name of registrant as specified in its charter)

———————

 

Nevada 333-186282 33-0864127
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

2929 East Commercial Blvd., PH-D, Fort Lauderdale, Florida 33308

(Address of Principal Executive Office) (Zip Code)

(954) 440-4678

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company    

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 
 

 

 
 

 

Item 8.01   Other Events.

 

On June 21, 2022, MediXall Group, Inc. issued a letter to its shareholders written by Noel J. Guillama-Alvarez, as the new Chairman of the Board of Directors and Interim CEO of MediXall Group, Inc. A copy of the letter is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01   Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1  

Letter to shareholders from Noel J. Guillama-Alvarez , as the new Chairman of the Board of Directors and Interim CEO of MediXall Group, Inc.

104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MediXall Group Inc.
     
     
Dated: June 21, 2022 By: /s/ Timothy Hart
  Name:

Timothy Hart

Title: Chief Financial Officer

 

 

 

 

 

EX-99.1 2 mdxl_99z1.htm MEDIXALL GROUP INC. RESIGNATION AND APPOINTMENTS DETAILS LETTER

EXHIBIT 99.1

Dear MediXall Group, Inc. Shareholders.

 

As I assume the role as Chairman of MediXall Group, Inc. (MDXL), I want to take a few moments and reflect on the MDXL vision and our prospects for the future. I also wish to express my appreciation to all MDXL shareholders as well as the management team and employees of MDXL/Health Karma that have helped to ignite our continued passion to improve Americans’ access to healthcare while reducing what they pay for it.

When Neil Swartz and I founded MediXall we envisioned a healthcare company that would bring transparency and objectivity to consumers and businesses seeking lowest-cost healthcare solutions in their community. Neil and the team that he assembled built the platform and Travis Jackson and Michael Swartz joined the team and through their insight they birthed Health Karma® our flagship enterprise.

I want to remind you that this team has successfully guided MDXL through what became two (2) years of some of the most difficult and disconcerning times of the COVID pandemic – while others failed, MDXL emerged strong. This is certainly due to stable and skilled leadership but also because MDXL was filling a void in the market during that difficult time and that will continue as difficult economic times persist. As Neil so aptly stated in his letter:

One of the largest factors in the ongoing success of MediXall/Health Karma is the stability of the healthcare industry and its importance to the wellbeing of everyone; it will always be needed regardless of the persons’ demographics or net worth."

Today, I am proud to have the opportunity to be working with this amazing team and continue to drive the vision and plan forward through what some see again as uncertain economic times, but are they uncertain for MDXL? As you will see, I don’t think so, and I’ll give you my perspective below.

First, where are we today? As noted, MDXL is strong and growing with additional paying subscribers added daily as the team works their way into the potential pool of 500,000 lives available through the nationwide distribution partners and affiliates the Company has developed.

As an inclusive Company, the MDXL Vision is holistic – we want to make available services to meet the needs of a person’s spirit, mind and body. This is why the inclusion of in-the-moment behavior health is such an important addition to the MDXL offering.

As we approach difficult economic times this component will be providing much needed services not only through the “Workers First” and “Responders First” programs but through direct access on our Health Karma platform. Again, MDXL continuess providing an amazing service to communities across the nation at a time when the need for our service offerings is rapidly growing.

 

PERSPECTIVE

I have been in heatlhcare for over 30 years, and I believe that we are in “the Right Place, at the Right Time, with the Right Products and Right Team.” Despite inflation and difficult economic conditions going forward, I am convinced that MDXL is positioned not just to weather the economic storms but to thrive – let me explain.

As a backdrop to my perspective let me remind you that based on Gross Domestic Product (GDP) the U.S. healtcare industry has not had a recession since 1960 when data started being tracked. That is over 60 years of continued growth in and out of several economic cycles, even in 1990 and again in 2008, the trend was irrefutible. Today, when we take into account that starting in 2012 and for two decades, there will be 10,000 people per day reaching 65 years old and becoming eligible for government sponsored healthcare- Medicare. As Neil observed, healthcare will “always be needed regardless of the persons’ demographics or net worth.”

 
 

 

We believe, the opportunituy for MDXL going forward with the opportunities Health Karma® provides is not only recession resistant but also a solution for companies trying to cut cost and a safety net for individuals and families who are left unemployed.

What validation is there for the claim that healthcare is recession resistant? Well, consider 60 years of historical data through periods as cloudy as what we face today. Further, consider that major banks and financial institutions are finding fair weather in the healthcare industry despite the fact that they believe the U.S. has entered or is about to enter a recession.

As of June 13, 2022, nearly every financial instruments (except for oil and commodities) has turned negative for the year, including, equities, bonds and cryptocurrency are down substantially – the NASDAQ alone is down around 30%. Where then can an investor turn for a sound and stable investment during these volatile times?

Recently, Bank of America released a report titled, “Health Care deep dive: 9 reasons it’s our favorite overweight” in which they stated on page one (1) the following:

·Health Care is statistically cheap, trading at a near-record discount to the S&P 500
·Health Care is the second fastest growing sector based on annualized EPS growth since 1986 - Tech is #1 but trades at a significant premium
·no matter what, we still have to eat and take our medicines – Health Care has a lower probability of negative earnings growth and lower earnings volatility than most sectors
·earnings call transcripts revealed Health Care as the most upbeat sector in 1Q
·longevity/aging demographics, plus the aftermath of a global pandemic, are likely to drive an acceleration in consumer and corporate spend

The volatility in the market due to the uncertainty regarding the extents and depth of the current round of inflation and the progression into a full recession is leaving many investors, including VC and PE firms, wondering about their investment strategy. The timing of the BofA report could not have been better as it clearly laid out a solid rationale for an investment in healthcare technology in these chaotic times.

I am convinced that MediXall, with our flagship solution Health Karma, is going to thrive and be a solution for both employers and consumers throughout the coming years – low-cost healthcare is in everyone’s budget!

As your new Chairman I wish our nation prosperity and God’s Blessing, our stakeholders, employees and affiliates health and prosperity as we go through 2022.

 

Thank you for your continued faith and support.

 

Noel J. Guillama-Alvarez

Chairman

 

 
 

 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. Specifically, the company's ability to raise additional capital, execute its business plan and strategy, sustain, or increase gross margins, achieve profitability, and build shareholder value are forward-looking statements. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

EX-101.SCH 3 mdxl-20220621.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mdxl-20220621_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mdxl-20220621_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jun. 21, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 21, 2022
Entity File Number 333-186282
Entity Registrant Name MediXall Group, Inc.
Entity Central Index Key 0001601280
Entity Tax Identification Number 33-0864127
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 2929 East Commercial Blvd.
Entity Address, Address Line Two PH-D
Entity Address, City or Town Fort Lauderdale
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33308
City Area Code (954)
Local Phone Number 440-4678
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 7 mdxl_8k_htm.xml IDEA: XBRL DOCUMENT 0001601280 2022-06-21 2022-06-21 iso4217:USD shares iso4217:USD shares 0001601280 false 8-K 2022-06-21 MediXall Group, Inc. NV 333-186282 33-0864127 2929 East Commercial Blvd. PH-D Fort Lauderdale FL 33308 (954) 440-4678 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://medxallgroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports mdxl_8k.htm mdxl-20220621.xsd mdxl-20220621_lab.xml mdxl-20220621_pre.xml mdxl_99z1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mdxl_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "mdxl_8k.htm" ] }, "labelLink": { "local": [ "mdxl-20220621_lab.xml" ] }, "presentationLink": { "local": [ "mdxl-20220621_pre.xml" ] }, "schema": { "local": [ "mdxl-20220621.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mdxl", "nsuri": "http://medxallgroup.com/20220621", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mdxl_8k.htm", "contextRef": "From2022-06-21to2022-06-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://medxallgroup.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mdxl_8k.htm", "contextRef": "From2022-06-21to2022-06-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medxallgroup.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001553350-22-000571-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001553350-22-000571-xbrl.zip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end